Navigation Links
Alfacell Receives NASDAQ Delisting Letter
Date:8/1/2008

nce in support of the Company's position at the hearing.

As disclosed in the Company's press releases on July 18, 2008 and June 26, 2008, the Company has also failed to comply with the $1 minimum bid price requirement under Marketplace Rule 4310(c)(4), the $2.5 million minimum stockholders' equity requirement under Marketplace Rule 4310(c)(3)(A) and the requirement for a minimum net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years under Marketplace Rule 4310(c)(3)( C). For continued listing on The NASDAQ Capital Market, the Company must comply with, among other requirements, at least one of the three alternative listing standards (market value, stockholders' equity or net income) and the minimum bid price requirement.

The Company is currently considering actions that may allow it to regain compliance with the NASDAQ continued listing standards and maintain its NASDAQ listing.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of ONCONASE in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently planning for Phase II clinical trials in other oncology indications. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alfacell Receives NASDAQ Non-Compliance Notification
2. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
3. Alfacell Announces Retirement of Chief Executive Officer
4. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
5. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
6. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
7. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
8. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
9. Alfacell to Present at BIO InvestorForum 2007
10. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
11. Workforce Alliance Receives U.S. Labor Departments Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... In her thought ... transports the reader to a not-so-distant future faced with an Ebola pandemic that is ... who overcomes personal tragedy to enter the world of counterterrorism, and who continues to ...
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 ... ... from top biopharmaceutical companies in the neuro and pain management space join prominent ... Joseph B. Martin Conference Center at Harvard Medical School in Boston. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based therapy ... at the Keck Graduate Institute and its collaborators. The discovery has the potential ... published online on August 27 by Scientific Reports, an open access research journal ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global ... chain risk management and resiliency practitioners with luminaries and thought leaders to advance ... be recognized for their innovations and performance excellence. At that time its principle ...
Breaking Biology Technology:Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3
... , , , 7.6.4 Long PCR , ... as desired with every temperature , command, enables a , ... , With Long PCR, this function can be used ... elongation. , , ...
... , , , , , ... set of conditions that can be applied to all PCR amplifications. For ... used, the annealing temperatures , of the PCRs can differ ... stringent annealing temperature is a prerequisite for reliable results , ...
... , , , , ... fragment using the PCR* are an everyday occurrence in the lab. For example, , ... which hinder, , or even prevent, further analyses (cycle ... of the PCR result. In such cases, PCR , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... acetyl CoA carboxylase 2,or ACC2, appears to turn the ... in part why the animals can eat more and ... Medicine,researchers.,The report that appears online today in the Proceedings ... cells in these mice bred to lack ACC2," said ...
... University,of California, San Diego have invented a process ... of specialized cells being sought as possible,treatments for ... and Shu Chien, UCSD bioengineering professors, and Christopher,J. ... in a paper published in the February issue ...
... have discovered a way to overcome one of the ... kill normal cells in the,process of eradicating cancer cells.,In ... of the Proceedings of the,National Academy of Sciences (PNAS), ... into a specially designed,virus. The virus eradicated prostate cancer ...
Cached Biology News:Lack of enzyme turns fat cells into fat burners 2Priming embryonic stem cells to fulfill their promise 2Priming embryonic stem cells to fulfill their promise 3Columbia research lifts major hurdle to gene therapy for cancer 2